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m4063 Routeto ChaosinVentricularFibrillationRevaaledbyTiasueSizeReduction
Y.-H. Kim, T. Ikeda, T.-J. Wu, C.A. Athill, A. Garfinkel, J.N. Weiss,
H.S. Karagueuzian, P.-S.Chen.
Wehavepresented evidence that ventricular fibrillation is deterministic chaos
arising from quasiperiodicify (QP).The purposeof this studywes to determine
whether the transition from chaos (VF) to QP, to periodicity (ventricular
tschycardia, VT) could be produced by progressivelydecreasing tieme size.
In RV free wall, mbrane potentials (TMPs) were
recorded on the endocardium, and simultaneous computerized mapping
(480 bipolar electrodes, 1.6 mm resolution) was dona on the epicardium
during VF. The tissue size was progressively reduced by cutting. All tissues
fibrillated spontaneously. The critical mass to sustain VF wee 24.0 g (16.IY.
of heart weight). Between baseline and third cut, there was a reduction of
the maximum number of wavefronts (WF) (4.5 + 0.6 vs. 1.7 + 0.4, p <
0.01), an increaae of life-span of reentrant WF (2.0 + 1.0 vs. 6.6 + 4.1, p <
an increase of cycle length (102.6+ 10.9 ms vs. 144.1 + 27.8 ms, p
< 0.01), and an increase of mean diastolic interval (11.8 + 4.5 ms vs. 36.3
+ 18.2 ms, p < 0.01). At baseline, Polncar6 plot of TMP showed ring like
structure, and Fourierspaotrum showed Iowfrequency modulation, indicating
chaos arising via QP. After 40% size reduction, low frequency oscillations in
intervals and frequency spectrum, and a ring like structure in Poincar6 plot
were present, compatible with QP. After 50% reduction, regular pertodicity
appeared. A decrease of the number of oscillators (VVF)in VF
by tissue size reduction wasassaiated with a parallel conversion of chaotic
dynamics, through quasiperiodicify, to periodicity.
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Hy~rchol.atero,e~ia,~Pairs~~~r~i~~~aPa~iW,
Roleof NitricOxide
A.J. Maxwell, J. Niebauer, P.S.Lin, P.S.Tsao, D. Bernstein, J.P. Cooke.
We obsewed in a pilot study that apolipoprotein E knockout
(apoE) mice exhibit asignifieantlyrSduCSdmaximaloxygen uptake (V02mex)
in responseto treadmill tesfingcampared towildtypa controls. Thisstudy was
performed to confirm and expand this obsewation toothermeasures of aero-
biccepacity; to determine if this effect is secmdaty to hypercholesterolemia;
and to explore possible mechanisms.
Methods and Results: Eight week old wild type (n = 30) and apoE
C57BU6J mice (n = 16) were divided into groups receiving either a regular
chcwor high cholesterol diet. At the beginning of the study,and again aftera4
week period, the mice were treadmill-tested to
exerciee capacity (V02, respiratory quotient (RQ), anaerobic threshold (AT),
diefenee run to exhaustion (DISTe), and aerobic work capacity (AWC)). At
sacrifice, aortae were hawested fordetenmination of endotheliumdepandent
and independent vascular relaxation and stimulated aortic NO production. At
eight weeks of age, exercise capacity was similar in both wild type and apoE
mice. However, by 12weeka of age, exercise capacity had deteriorated in the
apoE and the cholesterol fed mice. The V02mex, AT, the change in DISTe
from fr to 12 weeks (ADISTe) and AWC were inversely related (p = 0.03,
0.004, 0.0001 and 0.05, respectively) and the RQ at exhaustion was directly
related (p= 0.01) to serum cholesterol level. Hyparchoiesterolemia inhibited
endotheliumdepandent vascular relaxation in the apoE groups compared
with wild type mice (p < 0.02). There was an inverse trend between aortic
nitric oxide production and total cholesterol (r= –36, p = 0.06).
This is the first study to indicate that hyparcholesterolemia
impairs exercise capacity. The degree of impairment is correlated with the
level of senrm cholesterol. This effeef occurs in both diet-induced and genet-
iesfly determined hypercholesterolemic mice. The dysfunction is correlated
with a reduction in endotheliumdependent relaxation and endothelial nitric
oxide production.
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n4065 Ueeof MicrobubbleDestructionasa NovelApproachfor’Quantificationof MyocardialPerfuaion
WithContrastEchocsrdiogrsrphyDuringVenous
Infusionof Contrast
K. Wei, S. Fircozan, A.R. Jayaweere, D.M. Skyba, N.C. Goodman, S, Kaul.
Charfotteaville,
Quantification of myocardial perfusion is difficult from a venous injection of
microbubbles using echocsrdiography. We hypothesized that ultrasound in-
duced bubble destruction can be used for quantifying myocardial perfusion
during venous administration of microbubbles. If bubbles are administered
as a continuous infusion, then destroying them in the myocardium and mea-
suring their myocardial rate of reappearance will provide a measure of mean
myocardial microbubble velocity. In-vitro experiments were performed where
either flow was held constant and pulsing intewal was altered or vice versa,
In-vivo experiments involved ‘6 dogs whose IAD was cannulated and ike
flow set at 5-6 rates using a roller-pump. Microbubbles (MRX-115) were
delivered as a constant infusion and imaging was performed at end-systole
with another ultrasound pulse applied at varying intewals prior to that. Video
intensity in the systolic image was then plotted against the pulsing intewal
and the relation was fit to an expcmential function y = A (l-e-Et), where y is
video intensity at a pulsing interval t, A is the peak video intensity, and B is
the rate constant that determines the initial rate of rise of video intensity. Both
in the in vitro and in vivo experiments, an excellent correlation was found
between flow and the rate constant B (ranging from r = 0.66 to r = 0.98).
It is concluded that myocardial perfusion can be quantified during venous
infusion of contrast with a novel approach that utilizes the destruction of
microbubbles during ultrasound exposure.
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I l~en~fiCationofthe Firatf-ocusforFamilialAtrial
FlbnllattonUtilizinga RapidNovelPooledDNA
Strategy
R. Brugada, T. Tapscott, G. Czernuszewicz, A.J. Marian, A. Iglesias,
J. Girona, A. Domingo, L. Mont, J. Brugada, L.L. Bachinski, R. Roberts.
o
Atnal fibrillation is the most common suatained dysrhythm encountered in
clinical practice and is said to account for over one third of all strokes overthe
age of 65 years. It affects over 2 million Americans. Since preaent therapy ia
ineffective in preventing or eliminating AF, the therapeutic aim is to control the
rate of the ventricular response while utilizing antiplatelet and anticoagulant
therapy to decreaae the incidence of systemic emboli, particularly to the
brain. The total emotional, medical and financial burden imposed by chronic
medical therapy and the subsequent high incidence of stroke is immense.
The total cost is estimated at rnorethan $9 billion a year. Amolecularbasisfor
AF has yet to be determined. One approach, which has been successful for
metabolic dieorders, is to identify the defective gene responsible forafamilial
form of the disease. Accordingly, we identified a family of 26 members
in which atrial fibrillation was segregating as a highly penetrant autosomal
dominant disease. DNA from ail family members was mllacted and genotype
analysis wee conducted using short-tandem-repeat-polymorphic markers. A
novel approach utilizing pooled DNA samples allowed for rapid screening of
the genome which identified four regions of potential loci for the gene within
a few weeks. Linkage analysis was conducted on markers in these four
regions and LOD scores of 3.60 were obtained with the markers DIOS669
and DIOS607. Haplo~pe analysis using markers across a 70 CM region
revealed that the region co-segregating with the disease is located between
D1OS561and D1OSI866, an intewal of about 26cM located on chromosome
10q2.Thus, we have identified thefirst bcueforfamilial atrialfibrillation. Using
a novel genome screening strategy in an autosomal dominant diseaae, we
reduced the time to identify the locus by more than 75Y0.Application of thia
novel strategy in the future will reduce time and cost to identify new disease
related genes. Identification of the gene in this family should elucidate the
mechanism responsible for the familial form and also for the more common
acquired form of the disease and provide new and more effective therapy.
